Biotechnology stocks and sector-related exchange traded funds stood out on Tuesday after a U.S. District Court overruled President Donald Trump’s wishes to require drugmakers list prices on television advertisements.
Among the better performers on Tuesday, the SPDR S&P Biotech ETF (NYSEArca: XBI) increased 1.4% and First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT) advanced 1.6%. Meanwhile, the more widely observed iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) rose 1.0%.
The decision to block the Trump administration’s rule to require drugmakers to disclose their products’ prices on TV ads will help pharmaceutical and biotechnology companies avoid some of the short-term costs that had weighed on those stocks in recent months, the Wall Street Journal reports.
The rule would have required drugmakers to list prices included on direct-to-consumer TV ads for most prescription drugs covered by Medicare and Medicaid. The new drug rule was completed in May and was set to take effect Tuesday before being blocked by a U.S. judge. Drugmakers argued the disclosure would confuse consumers into thinking they would have to pay more than they actually would for medications through their health insurance providers.
The move “bodes well for pricing efforts more broadly near term,” Jefferies Group LLC health-care trader Jared Holz said in a note.
newETFs.io respects the hard work of others and gives all credit to the remarkable folks at ETFTrends.com. This excerpt/article was pulled from their RSS feed; click here to view the original. Please note that on occasion, the RSS feed will not have the author. When this happens this site defaults the author to "News". Make no mistake, this excerpt/article was not created by newETFs.io, it was simply shared with you.